HTA Council Recommendation (as of 19 January 2026) As a final recommendation, the HTA Council recommends the government financing of Lenvatinib [4 mg/10 mg capsule] as first-line treatment for adults diagnosed with advanced or unresectable HCC who are not candidates for immunotherapy and/oranti-VEGF. Relevant Information Evidence and Relevant Documents Assessment History Back to Assessments Page
Atezolizumab + Bevacizumab [60 mg/mL, 20 mL vial for IV infusion + 25 mg/mL, 4 mL or 16 mL vial for IV infusion] for the treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC)
HTA Council Recommendation (as of 19 January 2026) As a final recommendation, the HTA Council recommends the government financing of atezolizumab [60 mg/mL, 20 mL vial for intravenous (IV) infusion] + bevacizumab [25 mg/mL, 4 mL or 16 mL vial for IV infusion] as preferred first-line treatment for adults diagnosed with advanced or unresectable hepatocellular continue reading : Atezolizumab + Bevacizumab [60 mg/mL, 20 mL vial for IV infusion + 25 mg/mL, 4 mL or 16 mL vial for IV infusion] for the treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC)
Rivaroxaban [15 mg and 20 mg film-coated tablet] for the prevention of myocardial infarction, cerebrovascular disease, and other cardiovascular events among patients with nonvalvular atrial fibrillation
HTA Council Recommendation (as of 18 April 2023) The HTA Council recommends the government financing of dabigatran [110 mg and 150 mg capsule] for the prevention of myocardial infarction, cerebrovascular disease, and other cardiovascular events among patients with nonvalvular atrial fibrillation (NVAF) and subgroup of NVAF patients through their inclusion in the PNF. Relevant Information continue reading : Rivaroxaban [15 mg and 20 mg film-coated tablet] for the prevention of myocardial infarction, cerebrovascular disease, and other cardiovascular events among patients with nonvalvular atrial fibrillation
Dabigatran [110 mg and 150 mg capsule] for the prevention of myocardial infarction, cerebrovascular disease, and other cardiovascular events among patients with nonvalvular atrial fibrillation (NVAF) and subgroup of NVAF patients
HTA Council Recommendation (as of 18 April 2023) The HTA Council recommends the government financing of dabigatran [110 mg and 150 mg capsule] for the prevention of myocardial infarction, cerebrovascular disease, and other cardiovascular events among patients with nonvalvular atrial fibrillation (NVAF) and subgroup of NVAF patients through their inclusion in the PNF. Relevant Information continue reading : Dabigatran [110 mg and 150 mg capsule] for the prevention of myocardial infarction, cerebrovascular disease, and other cardiovascular events among patients with nonvalvular atrial fibrillation (NVAF) and subgroup of NVAF patients
Apixaban [2.5 mg and 5 mg film-coated tablet] for the prevention of myocardial infarction, cerebrovascular disease, and other cardiovascular events among patients with nonvalvular atrial fibrillation (NVAF)
HTA Council Recommendation (as of 18 April 2023) The HTA Council recommends the government financing of apixaban [2.5 mg and 5 mg film-coated tablet] for the prevention of myocardial infarction, cerebrovascular diseases and other cardiovascular events among patients with NVAF and subgroups of NVAF patients through their inclusion in the PNF. Relevant Information Evidence and continue reading : Apixaban [2.5 mg and 5 mg film-coated tablet] for the prevention of myocardial infarction, cerebrovascular disease, and other cardiovascular events among patients with nonvalvular atrial fibrillation (NVAF)